ATLANTA, Nov. 8, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.
Artivion's management team will present at the upcoming Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at the Lotte New York Palace. The Company's presentation is scheduled to begin at 9:45a.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
Members of the management team will also host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023. Due to the format of this event no webcast will be available.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.
Contacts: | |
Artivion | Gilmartin Group LLC |
D. Ashley Lee | Brian Johnston / Lynn Lewis |
Executive Vice President & | Phone: 332-895-3222 |
Chief Financial Officer | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Phone: 770-419-3355 |
| Last Trade: | US$46.55 |
| Daily Change: | -0.60 -1.27 |
| Daily Volume: | 745,875 |
| Market Cap: | US$2.210B |
November 06, 2025 November 06, 2025 August 07, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
